Clinical Trial

A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 2, multicenter, randomized, open-label, parallel group, blinded endpoint evaluation, active-controlled, dose-finding study.This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and enoxaparin 40 mg daily in subjects undergoing elective primary unilateral TKA.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-18.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT07140523
Lead Sponsor Sirius Therapeutics Co., Ltd.
Conditions Venous Thromboembolism
Enrollment 450 participants
Start Date 2025-09-16
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-15